Medical sensor specialist Lifecare ASA (OSE:LIFE) has submitted an application for regulatory approval to begin its first human clinical trial for a wireless continuous glucose monitoring (CGM) implant, the company announced on Tuesday.

The filing follows a finalised design phase, supporting trial preparations and continued progress in manufacturing development.

This milestone aligns with Lifecare's clinical and commercial roadmap, marking a significant step toward CE-mark certification.

Regulatory approval is anticipated in the third quarter of 2025, with trial completion expected by early fourth quarter, subject to timely authorisation.

Lifecare aims to begin its pivotal CE-mark clinical trial later this year, targeting completion in 2026.

Commercial launch of the CGM implant for human use is planned for 2027.